HAIC+STRIDE+Len

Phase 2Small molecule

SSulai Liu

HAIC+STRIDE+Len is one of 3 small molecule programs targeting Tremelimumab. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

TremelimumabRecruiting

TremelimumabPhase 2

Recruiting

Competition

Competitive Landscape

2 competitors in Tremelimumab

#DrugCompanyPhaseTrials

Imfinzi

AstraZeneca

Phase 2

8 2

Imjudo

AstraZeneca

Phase 2

6 3

HAIC+STRIDE+Len

SSulai Liu

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Tremelimumab1 trial

HAIC Combined With Durvalumab and Tremelimumab and Lenvatinib in uHCC

Recruiting·SSulai Liu·Phase 2·NCT06364007·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for HAIC+STRIDE+Len. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — HAIC+STRIDE+Len compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for HAIC+STRIDE+Len. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sulai Liu company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSulai Liu

HAIC+STRIDE+Len

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Tremelimumab1 trial

References

Drug Info

Quick Facts

Related News